JOURNAL OF KAOHSIUNG MEDICAL ASSOCIATION 2015. vol. 23, No.

(Bevacizumab)

Bevacizumab(Avastin
)

50

Bevacizumab

0.3%2.4%

1 FOLFIRI

4FOLFIRI

15%

(54

Bevacizumab

FOLFIRI

1364

2.29

Bevacizumab

Avastin

263

(Bevacizumab)

330

660

330

[4]Scappaticci

1.2.

3.

4.

[5]

[1]

(pneumatosis intestinalis)

1.Avastin [package insert]. South San

[2,3]

Francisco, CA: Genentech, Inc;

2011.www.gene.com/gene/products/

information/pdf/avastin-prescribing.pdf.

2.Saif MW, Mehra R. Incidence and

management of bevacizumab-related

Badgwell

toxicities in colorectal cancer. Expert

24

Opin Drug Saf 2006;5:553-66.

3.Asmis TR, Chung KY, Teitcher JB,

420

Kelsen DP, Shah MA. Pneumatosis

intestinalis: a variant of bevacizumab

264

 JOURNAL OF KAOHSIUNG MEDICAL ASSOCIATION 2015. vol. 23, No.3

related perforation possibly associated

5.Scappaticci FA, Fehrenbacher L,

with chemotherapy related GI toxicity.

Cartwright T, Hainsworth JD, Heim

Invest New Drugs 2008;26:95-6

W, Berlin J, Kabbinavar F, Novotny

4.Badgwell BD, Camp ER, Feig B,

W, Sarkar S, Hurwitz H . Surgical

Wolff RA, Eng C, Ellis LM, Cormier

wound healing complications in

JN. Management of bevacizumab-

metastatic colorectal cancer patients

associated bowel perforation: a case

treated with bevacizumab. J Surg Oncol

series and review of the literature. Ann

2005;91:17380.

Oncol 2008;19:57782.
(A)

(B)

(A)(B))
(B)

(A)

(A) (B))

265